secwatch.observer — SEC 8-K summary
======================================

Issuer:     Barinthus Biotherapeutics plc. (BRNS)
CIK:        0001828185
Form:       8-K/A
Filed at:   2025-08-08T23:59:59+00:00
Accession:  0001104659-25-075707
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Barinthus Bio amends 8-K to correct VTP-850 trial statement; reports Q2 net loss of $21.1M
--------------------------------------------------------------------------------

- Net loss $21.1M ($0.52/share) vs $19.7M ($0.49/share) in Q1 2025.
- Cash $87.8M, down $12.8M from Q1; runway unchanged into 2027.
- R&D expense $8.0M, down from $8.3M; G&A $15.4M, up from $12.6M.
- VTP-1000 AVALON MAD initiated, SAD data due early Q4 2025.
- Correction: Previous inaccurate sub-bullet on VTP-850 trial result replaced; trial complete, well tolerated, immunogenicity signs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1828185/000110465925075707/0001104659-25-075707-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1828185/000110465925075707/tm2523009d1_8ka.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-075707

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer